ALVO and ALVO SDB Related Headlines
Go Back- Alvotech to Report Financial Results for the First Quarter of 2026
- Alvotech Files Annual Report with the SEC
- Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
- Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
- UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)
- Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
- Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
- Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT
- Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland
- Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
- European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)
- Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors
- Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami
- Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million
ALVO and ALVO SDB Related Press Releases
Go Back- Alvotech to Report Financial Results for the First Quarter of 2026
- Alvotech Files Annual Report with the SEC
- Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
- Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
- UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)
- Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
- Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
- Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT
- Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland
- Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
- European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)
- Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors
- Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami
- Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million
